Heart failure: epidemiology, investigation and management

Medicine (United Kingdom)

Volumn 38, Issue 9, 2010, Pages 473-478

  Gardner, Roy S ^a   McDonagh, Theresa A ^b  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

cardiomyopathy; epidemiology; heart failure; investigation; prognosis; treatment

Indexed keywords

EID: 84927922564     PISSN: 13573039     EISSN: 13654357     Source Type: Journal    
DOI: 10.1016/j.mpmed.2010.06.005     Document Type: Review

References (40)

1. McDonagh, T.A., Morrison, C.E., Lawrence, A., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350 (1997), 829–833.
2. Ho, K.K., Pinsky, J.L., Kannel, W.B., Levy, D., The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22 (1993), 6A–13A.
3. Cowie, M.R., Wood, D.A., Coats, A., et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 20 (1999), 421–428.
4. Cowie, M.R., Wood, D.A., Coats, A.J., et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83 (2000), 505–510.
5. Levy, D., Kenchaiah, S., Larson, M.G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 (2002), 1397–1402.
6. The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
7. The CONSENSUS trial study group, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 316 (1987), 1429–1435.
8. The SOLVD Investigators, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. [published erratum appears in N Engl J Med 1992 Dec 10; 327(24): 1768] N Engl J Med 327 (1992), 685–691.
9. Anonymous, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. [see comments] Lancet 353 (1999), 9–13.
10. Packer, M., Coats, A.J., Fowler, M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001), 1651–1658.
11. Packer, M., Bristow, M.R., Cohn, J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996), 1349–1355.
12. Olsen, S.L., Gilbert, E.M., Renlund, D.G., Taylor, D.O., Yanowitz, F.D., Bristow, M.R., Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. [see comments] J Am Coll Cardiol 25 (1995), 1225–1231.
13. Anonymous, Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia–New Zealand Heart Failure Research Collaborative Group Circulation, 92, 1995 212–18.
14. Bristow, M.R., Gilbert, E.M., Abraham, W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996), 2807–2816.
15. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). [see comments] Lancet 353 (1999), 2001–2007.
16. Poole-Wilson, P.A., Swedberg, K., Cleland, J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003), 7–13.
17. Flather, M.D., Shibata, M.C., Coats, A.J.S., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005), 215–225.
18. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. [see comments] N Engl J Med 341 (1999), 709–717.
19. Pitt, B., Remme, W., Zannad, F., et al., for the Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med 348 (2003), 1309–1321.
20. McMurray, Jj V., Ostergren, J., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003), 767–771.
21. Cohn, J.N., Johnson, G., Ziesche, S., et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of patients with chronic congestive heart failure. N Engl J Med 325 (1991), 303–310.
22. Cohn, J.N., Archibald, D.G., Ziesche, S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986), 1547–1552.
23. Taylor, A.L., The African American Heart Failure Trial: a clinical trial update. Am J Cardiol 96:suppl (2005), 44i–48i.
24. Neuberg, G.W., Miller, A.B., O'Connor, C.M., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002), 31–38.
25. Batin, P., Wickens, M., McEntegart, D., Fullwood, L., Cowley, A.J., The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 16 (1995), 1613–1618.
26. Anonymous, The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group [see comments] N Engl J Med 336 (1997), 525–533.
27. Packer, M., Gheorghiade, M., Young, J.B., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study [see comments] N Engl J Med 329 (1993), 1–7.
28. Rathore, S.S., Wang, Y., Krumholz, H.M., Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347 (2002), 1403–1411.
29. Rathore, S.S., Curtis, J.P., Wang, Y., Bristow, M.R., Krumholz, H.M., Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003), 871–878.
30. Massie, B.M., Collins, J.F., Ammon, S.E., et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119 (2009), 1616–1624.
31. Kjekshus, J., Apetrei, E., Barrios, V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 357 (2007), 2248–2261.
32. Tavazzi, L., Maggioni, A.P., Marchioli, R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 1231–1239.
33. Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
34. Guillo, P., Mansourati, J., Maheu, B., et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 79 (1997), 1276–1278.
35. Belardinelli, R., Georgiou, D., Cianci, G., Purcaro, A., Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. [see comments] Circulation 99 (1999), 1173–1182.
36. Opasich, C., Febo, O., Riccardi, P.G., et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol 78 (1996), 354–357.
37. Dickstein, K., Cohen-Solal, A., Filippatos, G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 29 (2008), 2388–2442.
38. Gardner RS, McDonagh TA, Walker NL. Heart failure. Oxford: Oxford University Press, 2007.
39. NICE, Guideline, Chronic heart failure. Available from www.nice.org.uk/.
40. SIGN Guideline 95: Management of chronic heart failure. Available on www.sign.ac.uk/pdf/sign95.pdf.